The Trump administration and Pfizer reached a deal to bolster the supply of the coronavirus vaccine made by Pfizer and BioNTech for the United States by 100 million doses by the end of July.
The new agreement means the companies will supply the United States with a total of 200 million doses, enough to vaccinate 100 million Americans. The additional shots will cost $1.95 billion, the companies said.
The agreement, announced Wednesday, would help the United States at least partly offset a looming vaccine shortage that could leave millions of adult Americans uncovered in the first half of 2021.
So far, only two pharmaceutical companies — Pfizer and Moderna — have won federal authorization for emergency distribution of Covid-19 vaccines, and most of what they are capable of producing for the next six months has already been allocated through contracts with the United States and other governments.